Evidence map›Paper›PMID 41184543›Full record

ArticleNature genetics2025

Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer.

Sonia Boscenco, Jacqueline Tait-Mulder, Minsoo Kim, Cerise Tang, Tricia Park, Flora McNulty, Sergio Lilla, Sara Zanivan, Alejandro Huerta-Uribe, Benan Nalbant and 10 more

Abstract read
In one paragraph

Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sonia Boscenco *Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jacqueline Tait-Mulder *Cancer Research UK Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-2834-8714
Minsoo Kim *Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cerise TangComputational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tricia ParkComputational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4471-004X
Flora McNultyCancer Research UK Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0001-9555-0520
Sergio LillaCancer Research UK Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-3142-7640
Sara ZanivanCancer Research UK Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0002-9880-9099
Alejandro Huerta-UribeSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Benan NalbantDepartment of Computational and Systems Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark ZuckerDepartment of Pathology, New York University, New York, NY, USA.
David SumptonCancer Research UK Scotland Institute, Glasgow, UK.
Geoffray MonteuuisDepartment of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Christopher B JacksonDepartment of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-1035-6417
Wei WeiDepartment of Clinical Neuroscience, School of Clinical Medicine, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-2945-3543
Patrick F ChinneryDepartment of Clinical Neuroscience, School of Clinical Medicine, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-7065-6617
Ronan ChaligneDepartment of Computational and Systems Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4332-3291
Caleb A LareauDepartment of Computational and Systems Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4179-4807
Ed ReznikComputational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. reznike@mskcc.org.ORCID http://orcid.org/0000-0002-6511-5947
Payam A GammageCancer Research UK Scotland Institute, Glasgow, UK. payam.gammage@glasgow.ac.uk.ORCID http://orcid.org/0000-0003-1968-1726

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
The Human DNA virome: from petabase scale to single-cell resolutionU01AT012984 · NCCIH · SLOAN-KETTERING INST CAN RESEARCH · PI Caleb Andrew Lareau · 2024 to 2026
$5.2M
Defining the function of Complex I truncating mutations in cancerR37CA276200 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Payam Gammage, Eduard Reznik · 2023 to 2026
$2.5M
Charting somatic evolution via single-cell multiomicsR00HG012579 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI LAREAU, CALEB ANDREW · 2023 to 2025
$747k
Cancer Research UK (CRUK) A31287 and A_BICR_1920_GammageNCCIH NIH HHS U01 AT012984NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA276200NHGRI NIH HHS R00 HG012579U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA276200Wellcome Trust
6 · The paper itself

Abstract

The vast majority of recurrent somatic mutations arising in tumors affect protein-coding genes in the nuclear genome. Here, through population-scale analysis of 14,106 whole tumor genomes, we report the discovery of highly recurrent mutations affecting both the small (12S, MT-RNR1) and large (16S, MT-RNR2) mitochondrial RNA subunits of the mitochondrial ribosome encoded within mitochondrial DNA (mtDNA). Compared to non-hotspot positions, mitochondrial rRNA hotspots preferentially affected positions under purifying selection in the germline and demonstrated structural clustering within the mitoribosome at mRNA and tRNA interacting positions. Using precision mtDNA base editing, we engineered models of an exemplar MT-RNR1 hotspot mutation, m.1227G>A. Multimodal profiling revealed a heteroplasmy-dependent decrease in mitochondrial function and loss of respiratory chain subunits from a heteroplasmic dosage of ~10%. Mutation of conserved positions in ribosomal RNA that disrupt mitochondrial translation therefore represent a class of functionally dominant, pathogenic mtDNA mutations that are under positive selection in cancer genomes.

Indexed as

MutationNeoplasmsRNA, RibosomalDNA, MitochondrialHumansMitochondriaRNA, MitochondrialDNA, MitochondrialRNA, MitochondrialRNA, RibosomalRNA, ribosomal, 12S

Identifiers

PMID41184543
PMCPMC12597822

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.